Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 500-509

  Furst, Daniel E ^a   Clarke, Ann ^b   Fernandes, Ancilla W ^c   Bancroft, Tim ^d   Gajria, Kavita ^c   Greth, Warren ^c   Iorga, Serban R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MEDIMMUNE   (United States)

^d OPTUM   (United States)

Author keywords

Costs; Lupus nephritis; Neuropsychiatric lupus; Resources

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BILLING AND CLAIMS; CENTRAL NERVOUS SYSTEM DISEASE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICARE; NEUROPSYCHIATRIC LUPUS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADULT; AGED; COMORBIDITY; COSTS AND COST ANALYSIS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; INSURANCE, HEALTH; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84875716208     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.772058     Document Type: Article

References (21)

1. Manson JJ, Isenberg DA. The pathogenesis of systemic lupus erythematosus. Neth J Med 2003;61:343-6
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7
3. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis 2006;1:6
4. Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002;61:409-13
5. Panopalis P, Clarke AE. Systemic lupus erythematosus: clinical manifestations, treatment and economics. Expert Rev Pharmacoecon Outcomes Res 2006;6:563-75
6. Francis L, Perl A. Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother 2009;10:1481-94
7. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608
8. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010;69:1603-11
9. Furst DE, Clarke AE, Fernandes AW, et al. Resource utilization and direct medical costs in adult systemic lupus erythematosus (SLE) patients from a commercially insured population. Lupus 2013; (Jan 22 Epub ahead of print)
10. Li T, Carls GS, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum 2009;61:755-63
11. Pelletier EM, Ogale S, Yu E, et al. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009;31:2653-64
12. Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009;51:66-79
13. Clarke AE, Panopalis P, Petri M, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008;47:329-33
14. Aghdassi E, Zhang W, St-Pierre Y, et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011;38:658-66
15. Zhu TY, Tam LS, Lee VW, et al. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009;48:564-8
16. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
17. Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claimsbased algorithms for identifying members of Medicare\+Choice health plans that have chronic medical conditions. Health Serv Res 2004;39:1839-57
18. Chibnik LB, Massarotti EM, Costenbader KH. Identification and validation of lupus nephritis cases using administrative data. Lupus 2010;19:741-3
19. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005;43:1130-9
21. Altman D, Cutler D, Zeckhauser R. Enrollee mix, treatment intensity, and cost in competing indemnity and HMO plans. J Health Econ 2003;22: 23-45